Evidence map›Paper›PMID 37680459›Full record

ArticleiScience2023

IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy.

Jintong Chen, Yunwei Zhang, Hua Zhang, Mingyue Zhang, He Dong, Tianxue Qin, Sujun Gao, Siqing Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Cytokines in cancer.Cancer cell · 2025
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jintong ChenDepartment of Cancer Immunology, First Hospital of Jilin University, Changchun 130061, China.
Yunwei ZhangDepartment of Hematology, First Hospital of Jilin University, Changchun 130061, China.
Hua ZhangDepartment of Gastrointestinal Surgery, First Hospital of Jilin University, Changchun 130021, China.
Mingyue ZhangDepartment of Gynecological Oncology, First Hospital of Jilin University, Changchun 130021, China.
He DongDepartment of Gynecological Oncology, First Hospital of Jilin University, Changchun 130021, China.
Tianxue QinDepartment of Hematology, First Hospital of Jilin University, Changchun 130061, China.
Sujun GaoDepartment of Hematology, First Hospital of Jilin University, Changchun 130061, China.
Siqing WangDepartment of Cancer Immunology, First Hospital of Jilin University, Changchun 130061, China.
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Th9 cells are powerful effector T cells for cancer immunotherapy. However, the underlying antitumor mechanism of Th9 cells still needs to be further elucidated. Here, we show that Th9 cells express high levels of not only IL-9, but also IL-24. We found that knockout of

Indexed as

CancerComponents of the immune systemImmunology

Identifiers

PMID37680459
PMCPMC10480301
OpenAlexW4385478259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.